Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From PR yesterday:
Revance continues to expect 2024 total net product revenue, which includes sales of DAXXIFY and the RHA Collection, to be at least $280 million.
MC is almost 1x 2024 sales.
I've heard that story before.
pricing of last offering was $6.25.
I bought 5k shares at $3.00. Don't like Foley, but at these levels, lol, the r/r is too tempting.
hate to beat a dead horse, but do you know what would make the share price go up? If they sacked Foley. From $35 to $3. What are they waiting for? Seriously, why does he have such a hold on the company?
Just as I suspected: it will drop into the $2s. I bought added a bit early. Will wait to add more. Good job, Foley. Swell guy.
Yah, right.
The biggest risk is Foley. Pro biotech investors, especially the big funds, know how important management is. I still can't believe Foley, after the sales and marketing fiasco, hasn't been relieved of his duties. Mind-boggling.
I mean, you're not wrong, though eols 1Q24 rev growth wasn't great with respect to last q. I get it, seasonality. But...
Thanks for the clarification. K.
I don't get it. How does Foley keep his job? Any BOD worth their salt, would have booted him a long time ago.
Oh, indeed I have! Take eols, for example. It affected them, but not as much. Foley loves to spend money. He should've been booted long ago.
Actually, it was a terrible Q. Rev was $51M; last Q $58M.
Nobody was expecting a homerun here. Not bad, I suppose.
Added a few pre-market. And why not? With these weight-loss drugs, gonna be a lot of flabby faces staring people in the mirror, asking for a lift. 60% said they would think about it. Money in the bank.
Anyone have a good read on 1Q24 revenue? Quarter ends this week.
LOL! What a clown you are! What circus did you pop up from? Five posts, and all basically the same. Going out of business vibe? Really?
From last quarter earnings:
"Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively.
– Q4 DAXXIFY volume up 22% over Q3 2023, with over two-thirds of Q4 revenue attributable to reordering accounts.
– 2024 product revenue guidance of at least $280 million, supporting blockbuster potential in U.S. aesthetics."
And these guys here--fools! Paying $6.25/share for a company going out of business! Hey, clownboy (or should I say, girl?), you think the bankruptcy speil helped them to sell shares? You never know. Some fools are always looking to buy into bankrupt biotechs.
Maybe this has already been posted, but here goes. From Jonah Lupton on X.
"In a recent survey (done by Needham) of users of GLP-1 drugs, 62% of the respondents said they are now more likely to get aesthetic/cosmetic procedures (to help with skin tightening) and/or begin using injectables like Botox and $EOLS Jeuveau as well as fillers to help with overall skin appearance.
This is bullish for $INMD and $EOLS (I own both). Also good for $ABBV which owns Allergan which makes Botox."
Of course, he didn't mention rvnc, but several others in the thread did.
I mean, the data from the survey makes sense. Overweight people who lose weight feel good about themselves, and when they look in the mirror, they might think, "Hey, while I'm at it, why don't I do something about my face?"
Could be onto something here.
I haven't posted in a while, but, it seems, earnings wasn't as bad as many expected here--no? In fact, I'd argue that it was very good. 2024 guidance as well. We are probably looking at $300M (Foley said "at last $280M." We will also have CD on board, bring in revenue.
In any case, I tripled down today at $5.30 after selling last night at $6.30. Largest position in my biotech portfolio. This is an easy buy.
Added a few today, after getting back in. Good r/r if one has the time.
Agreed. It's a winner LT. Just so much bad sentiment around the stock. Had the numbers been better, of course I wouldn't have risked it. But they weren't outstanding. Added a few more just now.
I sold today at $8.20 and bought back at $6.84, and why not? I took one look at the sales numbers and said, and compared them with the projections on this board, and said to myself, "This doesn't look great."
Not bad numbers. A good buy at these levels. Will add if it drops more.
IMO, if numbers are good, they should release them this week, during JPM.
Do you expect them to release numbers and guidance this week, during JPM?
When will we see the numbers? Next week?
What in the hell is wrong with this thing today, a few days prior to providing preliminary earnings and guidance? Hangover from lawsuit news yesterday?
Hope so. And hope they knock it out of the park. Thanks.
Are we sure there will announce preliminary numbers and guidance next week?
Any chance mgmnt will give 2024 guidance in the coming weeks?
Doubling 2023 sales? I'll take that.
Probably is FUD. He probably doesn't even know that it's TRUE:
some dude on Stocktwits, probably spreading FUD: “We are ahead of Q4 plan/sales quotas” - sales rep
Still say there's something more than nothing we don't know about.
The lawsuit?
Agreed. Just find the crushing, grueling downward trend troubling, when most bios are rebounding. Most.
Curious price action. What's holding it back? Of course, er sucked, but it looks like 4Q will be better. Lots of good press as well.
Is is the alleged lawsuit? Is it serious?
Thanks for the reply. Hard to take this price action. Hardly any upward movement at all.
What was the answer, if you don't mind my asking?
Does the lawsuit have legs? Apparently not.
while everyone else was crying, hysterically, the sky was falling, I calmly added. Nothing really has changed; in fact, over the last month or so, a lot of positive changes have been made, as well as the positive press they have been getting, namely, in Time Magazine and Glamour. Whatever you may say, the value of this company is worth more than a market cap of $500M. When it was at $4B, yes, it was certainly over-valued, and shorts did well to attack. Hopefully, it will find its own, real, value in due time.
Did you get the sense that they were heading in the right direction? It sure sounded like it in the 3Q cc.